1Y Target$48.00Near-term target
5Y Target$50.88Compound horizon
10Y Target$64.94Long-dated conviction
FCF$404mTTM · 03/26CFCF $404m — modest; watch for margin expansion · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+5.5%TTM YoYC+Revenue +5.5% — steady but below market-beating range
D/E0.35B+D/E 0.35 — healthy leverage, well below danger zone
P/E3.6xAP/E 3.6 — deep value; well below S&P median (~20x)
PEG0.87B+PEG 0.87 — near fair value, classic Lynch benchmark (1.0)
Why now
Marine Shipping · market cap $1.4b. 11% off the 52-week high of $42.70. PEG 0.87 — paying under fair value for the growth rate. 3 sell-side analysts publish a mean 1-yr target of $48.00 (implying +26% upside).
Moat
Net margin 51% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 22% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 107% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon
1-3 yr $48.00 (3-analyst consensus) — multiple re-rating thesis requires a catalyst. 5 yr $50.88 at ~6% CAGR — dividend + buyback compounding. 10 yr $64.94 if the moat survives secular pressure.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.